Loading…
Lobbying Spend
—
Filings
10
Firms Hired
1
Active Period
2017–2019
Client-reported lobbying expenses on LDA filings
Lobbying firms retained by this client; amounts are client-reported expenses when available
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
Allowing for the Safe Return of Rohingyas to Burma Act of 2019
2019 · third_quarter · Firm: CARMEN GROUP INCORPORATED
Work with Center for Medicare/ Medicaid Innovation on payment models that will help improve quality of care and outcome or cancer patients; Seek opportunities with Congress and the National Cancer Institute to highlight UPMC Hillman's Cancer Centers oncology care delivery initiatives; 340B program and regulations; HR 4392; Drug Pricing
Client expense: — · Firm income: —
Matched citations: HR 4392
Allowing for the Safe Return of Rohingyas to Burma Act of 2019
2019 · second_quarter · Firm: CARMEN GROUP INCORPORATED
Work with Center for Medicare/ Medicaid Innovation on payment models that will help improve quality of care and outcome or cancer patients; Seek opportunities with Congress and the National Cancer Institute to highlight UPMC Hillman's Cancer Centers oncology care delivery initiatives; 340B program and regulations; HR 4392; Drug Pricing
Client expense: — · Firm income: $29,000
Matched citations: HR 4392
Allowing for the Safe Return of Rohingyas to Burma Act of 2019
2019 · first_quarter · Firm: CARMEN GROUP INCORPORATED
Work with Center for Medicare/ Medicaid Innovation on payment models that will help improve quality of care and outcome or cancer patients; Seek opportunities with Congress and the National Cancer Institute to highlight UPMC Hillman's Cancer Centers oncology care delivery initiatives; 340B program and regulations; HR 4392; Drug Pricing
Client expense: — · Firm income: $44,000
Matched citations: HR 4392
To provide that the provision of the Medicare Program: Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems and Quality Reporting Programs final regulation relating to changes in the payment amount for certain drugs and biologicals purchased under the 340B drug discount program shall have no force or effect, and for other purposes.
2018 · fourth_quarter · Firm: CARMEN GROUP INCORPORATED
Work with Center for Medicare/ Medicaid Innovation on payment models that will help improve quality of care and outcome for cancer patients; Seek opportunities with Congress and the National Cancer Institute to highlight UPMC Hillman's Cancer Centers oncology care delivery initiatives; 340B programs and regulations; HR 4392; Drug Pricing
Client expense: — · Firm income: $44,000
Matched citations: HR 4392
To provide that the provision of the Medicare Program: Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems and Quality Reporting Programs final regulation relating to changes in the payment amount for certain drugs and biologicals purchased under the 340B drug discount program shall have no force or effect, and for other purposes.
2018 · third_quarter · Firm: CARMEN GROUP INCORPORATED
Work with Center for Medicare/ Medicaid Innovation on payment models that will help improve quality of care and outcome for cancer patients; Seek opportunities with Congress and the National Cancer Institute to highlight UPMC Hillman's Cancer Centers oncology care delivery initiatives; 340B programs and regulations; HR 4392
Client expense: — · Firm income: $44,000
Matched citations: HR 4392
Source: Senate LDA